Premium
Compliance and quality of response are major contributors to cost‐effective antidepressant therapy
Author(s) -
Feighner J. P.
Publication year - 1994
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470090705
Subject(s) - antidepressant , tricyclic , medicine , monoamine oxidase , psychiatry , tricyclic antidepressant , intensive care medicine , compliance (psychology) , psychology , pharmacology , anxiety , social psychology , biochemistry , chemistry , enzyme
Major depressive disorder is a common psychobiological disorder which is frequently recurrent with multiple life‐time episodes. Effective medical treatments primarily with the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have been available for many years, however, compliance and relapse have continued to be a significant problem. With the advent of newer antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), the issues of cost‐effectiveness have come into focus. Analysis of controlled antidepressant trials comparing SSRIs with TCAs have consistently demonstrated the cost‐effective advantage of the SSRIs over the TCAs, which is a direct reflection of the quality of response with better compliance, a more benign side effect profile and consistent advantage in clinical efficacy.